Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Immunotech Biopharm Ltd ( (HK:6978) ) is now available.
Immunotech Biopharm reported that for the year ended 31 December 2025, other income fell sharply, research and administrative expenses declined, but net other losses surged, leading to an increased annual loss of RMB230.9 million compared with the previous year. Operationally, the company advanced its oncology pipeline, completing enrolment of 430 subjects in a Phase II trial for its core EAL therapy, which is now under conditional NDA review with priority status in China, while its 6B11-OCIK ovarian cancer candidate completed Phase I enrolment and interim analysis, with Phase II to be initiated in line with future operational plans.
The most recent analyst rating on (HK:6978) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Immunotech Biopharm Ltd stock, see the HK:6978 Stock Forecast page.
More about Immunotech Biopharm Ltd
Immunotech Biopharm Ltd is a biotechnology company focused on cellular immunotherapy for cancer treatment. Its core products include EAL, a broad-spectrum anti-tumour T-cell therapy derived from patients’ peripheral blood, and 6B11-OCIK Injection, an autologous cytotoxic T lymphocyte treatment targeting ovarian cancer, with a primary market focus in mainland China.
Average Trading Volume: 368,440
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.49B
Find detailed analytics on 6978 stock on TipRanks’ Stock Analysis page.